Ilyas Sahin, Assistant Professor of Medicine at Harvard Medical School, shared on X:
“Another major ESMO26 paper, published in NEJM today. In PD-L1-negative advanced nonsquamous lung cancer, sacituzumab tirumotecan (a TROP2-targeted ADC) plus pembrolizumab improved median PFS (time without progression) from 5.7 to 15 months, replacing chemotherapy rather than adding to it.
OS is immature, and these China-only results need global confirmation.”
Title: Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC
Authors: Fei Zhou, Xiangjiao Meng, Qingqing Ding, Peng Zhang, Wenhua Liang, Sanxing Guo, Yan Yu, Wenxiu Yao, Yun Fan, Xingxiang Pu, Chunling Liu, Jiuwei Cui, Peng Chen, Hua Zhong, Yongsheng Wang, Zhangzhou Huang, Zhi Xu, Xiaorong Dong, Tienan Yi, Ying Hu, Qiming Wang, Bolin Chen, Hui Wang, Longhua Sun, Lang He, Wei Zheng, Yina Wang, Xiaochen Zhang, Yu Yao, Yongsheng Li, Zhe Yang, Feng Ye, Xia Song, Ming Zhou, Li Yin, Yan Qing, Xiaoping Jin, Junyou Ge, Caicun Zhou
Read the Full Article.
You can also read: OptiTROP-Lung06: Sac-TMT Plus Pembrolizumab Outperforms Chemoimmunotherapy in PD-L1–Negative NSCLC
